Systemic assessments utilizing saliva: Part 2 - Osteoporosis and use of saliva to measure bone turnover

International Journal of Prosthodontics

Volumn 19, Issue 1, 2006, Pages 53-60

  Koka, Sreenivas ^a,b   Forde, Michael D ^a   Khosla, Sundeep ^a  

^a MAYO CLINIC   (United States)

^b Division of Prosthodontics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

BONE; BONE DENSITY; BONE DEVELOPMENT; CHEMISTRY; FORECASTING; HUMAN; METABOLISM; OSTEOLYSIS; OSTEOPOROSIS; PHYSIOLOGY; REVIEW; SALIVA;

BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; BONE RESORPTION; FORECASTING; HUMANS; OSTEOGENESIS; OSTEOPOROSIS; SALIVA;

EID: 32644432375     PISSN: 08932174     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. World Health Organization. Report of a WHO study group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. World Health Organ Tech Rep Ser 1994;843:1-129.
2. Jordan KM, Cooper C. Epidemiology of osteoporosis. Best Pract Res Clin Rheumatol 2002;16:795-806.
3. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures [see comment]. Lancet 2002;359:1761-1767.
4. Gullberg B, Johnell O, Kanis JA. World-wide projections for hip fracture. Osteoporos Int 1997;7:407-413.
5. Riggs BL, Melton LJ III, Robb RA, et al. Population-based study of age and sex differences in bone volumetric density, size, geometry, and structure at different skeletal sites. J Bone Miner Res 2004;19:1945-1954.
6. Riggs BL, Khosla S, Melton LJ III. Sex steroids and the construction and conservation of the adult skeleton. Endocrine Rev 2002;23:279-302.
7. Khosla S, Melton LJ III, Atkinson EJ, O'Fallon WM, Klee GG, Riggs BL. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: A key role for bioavailable estrogen. J Clin Endocrinol Metabol 1998;83:2266-2274.
8. Riggs BL, Melton LJ III. Involutional osteoporosis. N Engl J Med 1986;314:1676-1686.
9. Seeman E. Invited review: Pathogenesis of osteoporosis. J Appl Physiol 2003;95:2142-2151.
10. Melton LJ III, Johnell O, Lau E, Mautalen CA, Seeman E. Osteoporosis and the global competition for health care resources. J Bone Miner Res 2004;19:1055-1058.
11. Melton LJ III. The prevalence of osteoporosis: Gender and racial comparison. Calcif Tissue Int 2001;69:179-181.
12. Melton LJ III, Gabriel SE, Crowson CS, Tosteson AN, Johnell O, Kanis JA. Cost-equivalence of different osteoporotic fractures. Osteoporos Int 2003;14:383-388.
13. Gabriel SE, Tosteson AN, Leibson CL, et al. Direct medical costs attributable to osteoporotic fractures. Osteoporos Int 2002;13:323-330.
14. Green AD, Colon-Emeric CS, Bastian L, Drake MT, Lyles KW. Does this woman have osteoporosis? JAMA 2004;292:2890-2900.
15. National Osteoporosis Foundation. America's Bone Health: The State of Osteoporosis and Low Bone Mass in our Nation. Washington, DC: The Foundation, 2002.
16. Johnell O, Kanis J. Epidemiology of osteoporotic fractures. Osteoporos Int 2005;16(suppl 2):S3-S7.
17. Zethraeus N, Ben Sedrine W, Caulin F, et al. Models for assessing the cost-effectiveness of the treatment and prevention of osteoporosis. Osteoporos Int 2002;13:841-857.
18. Johnell O, Kanis JA. An estimate of the worldwide prevalence, mortality and disability associated with hip fracture. Osteoporos Int 2004;15:897-902.
19. Melton LJ III, Crowson CS, O'Fallon WM, Wahner HW, Riggs BL. Relative contributions of bone density, bone turnover, and clinical risk factors to long-term fracture prediction. J Bone Miner Res 2003;18:312-318.
20. Melton LJ III, Beck TJ, Amin S, et al. Contributions of bone density and structure to fracture risk assessment in men and women. Osteoporos Int 2005;16:460-467.
21. Khosla S, Melton LJ III, Robb RA, et al. Relationship of volumetric BMD and structural parameters at different skeletal sites to sex steroid levels in men. J Bone Miner Res 2005;20:730-740.
22. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures [see comment]. BMJ 1996;312:1254-1259.
23. Johnell O, Kanis JA, Oden A, et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res 2005;20:1185-1194.
24. Cefalu CA. Is bone mineral density predictive of fracture risk reduction? Curr Med Res Opin 2004;20:341-349.
25. Ammann P, Rizzoli R. Bone strength and its determinants. Osteoporos Int 2003;14(suppl 3):S13-S18.
26. Rubin CD. Treatment considerations in the management of age-related osteoporosis. Am J Med Sci 1999;318:158-170.
27. Garnero P. Markers of bone turnover for the prediction of fracture risk. Osteoporos Int 2000;11(suppl 6):S55-S65.
28. Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: The OFELY study. J Bone Miner Res 2000;15:1526-1536.
29. Ross PD, Kress BC, Parson RE, Wasnich RD, Armour KA, Mizrahi IA. Serum bone alkaline phosphatase and calcaneus bone density predict fractures: A prospective study. Osteoporos Int 2000;11:76-82.
30. Akesson K, Ljunghall S, Jonsson B, et al. Assessment of biochemical markers of bone metabolism in relation to the occurrence of fracture: A retrospective and prospective population-based study of women. J Bone Miner Res 1995;10:1823-1829.
31. van Daele PL, Seibel MJ, Burger H, et al. Case-control analysis of bone resorption markers, disability, and hip fracture risk: The Rotterdam study. BMJ 1996;312:482-483.
32. Christgau S, Bitsch-Jensen O, Hanover Bjarnason N, et al. Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy. Bone 2000;26:505-511.
33. Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J, Committee of Scientific Advisors of the International Osteoporosis Foundation. The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int 2000;11(suppl 6):S2-S17.
34. Johnell O, Oden A, De Laet C, Garnero P, Delmas PD, Kanis JA. Biochemical indices of bone turnover and the assessment of fracture probability. Osteoporos Int 2002;13:523-526.
35. Riggs BL, Khosla S. Role of biochemical markers in assessment of osteoporosis. Acta Orthop Scand Suppl 1995;266:14-18.
36. Garnero P, Dargent-Molina P, Hans D, et al. Do markers of bone resorption add to bone mineral density and ultrasonographic heel measurement for the prediction of hip fracture in elderly women? The EPIDOS prospective study. Osteoporos Int 1998;8:563-569.
37. Ravn P, Thompson DE, Ross PD, Christiansen C. Biochemical markers for prediction of 4-year response in bone mass during bisphosphonate treatment for prevention of postmenopausal osteoporosis. Bone 2003;33:150-158.
38. Stinson RA, Hamilton BA. Human liver plasma membranes contain an enzyme activity that removes membrane anchor from alkaline phosphatase and converts it to a plasma-like form. Clin Biochem 1994;27:49-55.
39. Seibel MJ. Molecular markers of bone turnover: Biochemical, technical and analytical aspects. Osteoporos Int 2000:11(suppl 6):S18-29.
40. Langlois MR, Delanghe JR, Kaufman JM, De Buyzere ML, Van Hoecke MJ, Leroux-Roels GG. Posttranslational heterogeneity of bone alkaline phosphatase in metabolic bone disease. Eur J Clin Chem Clin Biochem 1994;32:675-680.
41. Hauschka PV, Lian JB, Cole DE, Gundberg CM. Osteocalcin and matrix Gla protein: Vitamin K-dependent proteins in bone. Physiol Rev 1989;69:990-1047.
42. Gallop PM, Lian JB, Hauschka PV. Carboxylated calcium-binding proteins and vitamin K. N Engl J Med 1980;302:1460-1466.
43. Ducy P, Desbois C, Boyce B, et al. Increased bone formation in osteocalcin-deficient mice. Nature 1996;382:448-452.
44. Brown JP, Delmas PD, Malaval L, Edouard C, Chapuy MC, Meunier PJ. Serum bone Gla-protein: A specific marker for bone formation in postmenopausal osteoporosis. Lancet 1984;1:1091-1093.
45. Garnero P, Grimaux M, Seguin P, Delmas PD. Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro. J Bone Miner Res 1994;9:255-264.
46. Chen JT, Hosoda K, Hasumi K, Ogata E, Shiraki M. Serum N-terminal osteocalcin is a good indicator for estimating responders to hormone replacement therapy in postmenopausal women. J Bone Miner Res 1996;11:1784-1792.
47. Fessler LI, Morris NP, Fessler JH. Procollagen: Biological scission of amino and carboxyl extension peptides. Proc Natl Acad Sci USA 1975;72:4905-4909.
48. Liu SH, Yang RS, al-Shaikh R, Lane JM. Collagen in tendon, ligament, and bone healing. A current review. Clin Orthop Relat Res 1995;(318)265-278.
49. Parfitt AM, Simon LS, Villanueva AR, Krane SM. Procollagen type I carboxy-terminal extension peptide in serum as a marker of collagen biosynthesis in bone. Correlation with Iliac bone formation rates and comparison with total alkaline phosphatase. J Bone Miner Res 1987;2:427-436.
50. Ogawa T, Ono T, Tsuda M, Kawanishi Y. A novel fluor in insoluble collagen: A crosslinking moiety in collagen molecule. Biochem Biophys Res Comm 1982;107:1252-1257.
51. Fujimoto D, Moriguchi T, Ishida T, Hayashi H. The structure of pyridinoline, a collagen crosslink. Biochem Biophys Res Comm 1978;84:52-57.
52. Seibel MJ. Biochemical markers of bone metabolism in the assessment of osteoporosis: useful or not? J Endocrinol Investig 2003;26:464-471.
53. Seibel MJ. Biochemical markers of bone remodeling. Endocrinol Metabol Clin North Am 2003;32:83-113.
54. Eastell R, Colwell A, Hampton L, Reeve J. Biochemical markers of bone resorption compared with estimates of bone resorption from radiotracer kinetic studies in osteoporosis. J Bone Miner Res 1997;12:59-65.
55. Bienkowski RS. Intracellular degradation of newly synthesized collagen. Coll Relat Res 1984;4:399-411.
56. Franzen A, Heinegard D. Isolation and characterization of two sialoproteins present only in bone calcified matrix. Biochem J 1985;232:715-724.
57. Fisher LW, Whitson SW, Avioli LV, Termine JD. Matrix sialoprotein of developing bone. J Biol Chem 1983;258:12723-12727.
58. Oddie GW, Schenk G, Angel NZ, et al. Structure, function, and regulation of tartrate-resistant acid phosphatase. Bone 2000;27:575-584.
59. Minkin C. Bone acid phosphatase: Tartrate-resistant acid phosphatase as a marker of osteoclast function. Calcif Tiss Int 1982;34:285-290.
60. Forde MD, Koka S, Eckert SE, Carr AB, Wong DT. Systemic assessments utilizing saliva: Part 1. General considerations and current assessments. Int J Prosthodont 2006:19.
61. McGehee JW Jr, Johnson RB. Biomarkers of bone turnover can be assayed from human saliva. J Gerontol A Biol Sci Med Sci 2004;59:196-200.
62. Kivlighan KT, Granger DA, Schwartz EB, Nelson V, Curran M, Shirtcliff EA. Quantifying blood leakage into the oral mucosa and its effects on the measurement of cortisol, dehydroepiandrosterone, and testosterone in saliva. Horm Behav 2004;46:39-46.
63. Bullon P, Goberna B, Guerrero JM, Segura JJ, Perez-Cano R, Martinez-Sahuquillo A. Serum, saliva, and gingival crevicular fluid osteocalcin: Their relation to periodontal status and bone mineral density in postmenopausal women. J Periodontol 2005;76:513-519.